Article -> Article Details

Overview:

The global market report containing various details of the valley fever market predicted a substantial rise during the forecast period of 2018 to 2022. Market Research Future (MRFR) analyzed several factors as well to understand the movement of the market and how certain trends can inspire the market movement. 

The disease is also known as coccidioidomycosis, a type of fungal infection. It is commonly found in soil and dust across the world. However, it is more prevalent in the American region. Any type of activity like construction and farming that triggers a disruption in soil structure can release these bacteria into the air. People around those areas, if inhale the same air, would contract the disease and it can be fatal. Government initiatives to boost awareness related to the disease and increasing expenditure to find a proper cure are expected to inspire market growth.

Segmentation:

The global understanding of the valley fever market reveals segments like the site of infection and treatments to understand the nuances of the market. This segmentation allows a decent analysis of the changes in the market that has been backed by scientific approaches, volumes and values, and aspects.

By site of infection, the global market on the valley fever has been segmented into liver, bones, skin, brain, heart, and membranes that share a connection with the brain and spinal cord and others. 

By treatments, the understanding of the global valley fever market has been segmented into itraconazole, posaconazole, voriconazole, fluconazole, and others. 

Regional Analysis:

The Americas would dominate the global market as the region displays the maximum number of cases each year. Government initiatives, availability of medicine, and others are expected to provide thrust to the market. In addition, local awareness regarding the disease is high, which would influence the market outcome. 

Competitive Landscape:

Johnson and Johnson, Novartis, Anacor Pharmaceuticals, Bristol Meyer Squibb, Valeant Pharmaceutical, Galderma S.A., Pfizer Inc., GlaxoSmithKline Pharmaceuticals Limited, and others are some of the prominent names associated with the global valley fever market that can trigger better growth during the forecast period. These companies are relying heavily on strategic mechanisms like a merger, acquisition, innovation, research funding, development of treatment, and others to ensure growth for themselves and for the market. MRFR learned of its latest measures to understand how various trends would inspire the market in the coming days. 

Industry News:

In July 2020, the Chinese Consulate General in Los Angeles issued a warning to the Chinese citizens residing in the southwest regions of the United States, stating that they should learn more about Valley Fever, a fungal infection. This awareness would help in take better preventive measures and get treatment for the same. In Phoenix, the capital city of Arizona state, three Chinese people had already contracted the disease and two of them died from the disease. 

In July 2020, the Food and Agriculture Organization (FAO) department of the United Nations (UN) donated protective gears worth around USD 5 million to the Ugandan government to fight rift valley fever. This is a step to ensure food security in the region. 

The COVID-19 pandemic has taught countries well about getting prepared for diseases that can take the shape of an epidemic. This also opened avenues that boosts a proper reading of bacterial or fungal diseases that can turn fatal and spread easily. In fact, the decision of the Chinese government to make their people aware about the situation in Arizona affirms this condition.